BWX Technologies, Inc. (BWXT): Results of Operations and Financial Condition
BWX Technologies, Inc. (BWXT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 bwxt_63026xerexhibit991.htm EX-99.1 Document BWX Technologies Reports Second Quarter 2026 Results • 2Q26 revenues of $901.6 million • 2Q26 net income of $89.1 million, adjusted EBITDA (1) of $155.5 million • 2Q26 diluted GAAP EPS of $0.97, non-GAAP (1) EPS of $1.07 • An
How this was made
The 30-second read
Why it matters
The company raised full-year 2026 guidance across adjusted EBITDA, non-GAAP EPS, and free cash flow, citing strong execution, Commercial Operations growth, and PCG contribution, while shifting focus away from medical.
Market read
This is a primary earnings and guidance update with explicit upward ranges, making it a direct input to near-term valuation and positioning.
What to watch
Free cash flow guidance and working-capital timing can swing quarter to quarter; traders should watch whether 2H26 execution matches the raised ranges.
Background
BWX Technologies filed an 8-K for 2Q26 results, including a sale of its medical business and the recently closed Precision Components Group (PCG) acquisition.
Ticker impact
BWX Technologies reported 2Q26 results and raised 2026 adjusted EBITDA to $662M-$672M, non-GAAP EPS to $4.70-$4.80, and FCF to $345M-$360M.
Likely near-term positive bias as traders reprice 2026 EBITDA, EPS, and free cash flow expectations.
The filing is a primary disclosure (8-K with earnings release) and includes explicit upward guidance ranges and quarterly financial results, which typically drive repricing versus prior guidance.
Market effects
Reinforces demand visibility in nuclear national security and commercial nuclear power supply chains, potentially supporting sentiment for defense-nuclear and nuclear components peers.
Limited direct regional impact; company-specific nuclear supply chain narrative may influence broader US defense-industrial sentiment.
Moderate, as nuclear power and defense supply chains are globally relevant but the disclosure is primarily US-focused.
Counterpoint
Commercial Operations growth may be partly acquisition- and mix-driven, so organic demand durability could be less strong than headline guidance implies.
Key entities
- public_companyBWX Technologies, Inc.
Reported 2Q26 financial results and raised 2026 guidance; announced sale of medical business and PCG acquisition contribution.
- acquired_businessPrecision Components Group, LLC (PCG)
Acquisition closed July 1, 2026, establishing a US footprint for commercial nuclear component manufacturing and included in 2026 guidance.
- divested_businessMedical business
Announced sale enables increased focus on core nuclear national defense and commercial nuclear power markets.
